Cooley partner Yiming Liu and associate Alex Wu co-authored an article for Hong Kong Business discussing their 2026 outlook for the biotechnology industry in China, the increase in deal activity in 2025 and how Hong Kong has reemerged as a critical financial market for the industry. The article also highlights the positive reaction to the Hong Kong Stock Exchange Chapter 18A initial public offerings and the globalization of business development through asset-level out-licensing and newly formed company spinouts.

This article was first published on Hong Kong Business here and Healthcare Asia here.

Related Contacts

Yiming Liu
Partner in Charge – Shanghai
Shanghai
Alex Wu
Associate
Shanghai

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.